Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
mRNA-5671
i
Other names:
mRNA-5671, mRNA 5671, V941, mRNA5671, V-941, V 941
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Moderna
Drug class:
KRAS inhibitor
Related drugs:
‹
MRTX1257 (4)
AZD4785 (1)
QTX3034 (1)
ATG-012 (0)
ELI-002 7P (0)
KRAS peptide vaccine (0)
SLATE-KRAS (0)
anti-KRAS G12D mTCR PBL (0)
siG12D LODER (0)
MRTX1257 (4)
AZD4785 (1)
QTX3034 (1)
ATG-012 (0)
ELI-002 7P (0)
KRAS peptide vaccine (0)
SLATE-KRAS (0)
anti-KRAS G12D mTCR PBL (0)
siG12D LODER (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (NCT03948763)
Phase 1
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Completed
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
09/07/2022
Initiation :
06/26/2019
Primary completion :
08/25/2022
Completion :
08/25/2022
EGFR • KRAS • ALK • MSI
|
KRAS mutation • EGFR mutation • EGFR positive • HLA-A*11
|
Keytruda (pembrolizumab) • mRNA-5671
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login